Drugs / LCP-Tacro
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT01666951 | Nov 2012 → Mar 2013 | kidney failure | Veloxis Pharmaceuticals | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT01187953 | Sep 2010 → Mar 2013 | kidney failure | Veloxis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00817206 | Dec 2008 → Feb 2011 | kidney failure | Veloxis Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LCP Tacro | “maintenance immunotherapy with LCP Tacro™ tablets (tacrolimus, LifeCycle Pharma A/S, Hoersholm, Denmark) once daily” NCT00817206 ↗ |
| Route | Oral | “LCP-Tacro tablets will be administered orally QD” NCT00817206 ↗ |